Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications

Shots:

• AbCellera to receive upfront, milestone, and royalties based on the development and commercialization of Abs, emerge under the collaboration
• The expanded collaboration will utilize AbCellera’s technology stack, which includes Trianni Mouse and OrthoMab protein engineering platform
• AbCellera will generate panels of Abs against up to 8 new targets across multiple indications, selected by Gilead

Click here to­ read full press release/ article | Ref: BusinessWire | Image: Business In Vancouver